Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
2 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
3 Adipocytokine signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
4 Adrenergic signaling in cardiomyocytes 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
5 African trypanosomiasis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
6 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
7 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
8 Alcoholic liver disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
9 Aldosterone synthesis and secretion 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
10 Allograft rejection 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
11 Allograft rejection 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
12 Allograft rejection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
13 Alzheimer disease 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
14 Alzheimer disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
15 Amoebiasis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
16 AMPK signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
17 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
18 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
19 Antifolate resistance 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
20 Antigen processing and presentation 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
21 Apelin signaling pathway 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
22 Apelin signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
23 Apoptosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
24 Asthma 💬
 1件: FCER1A 💬 Omalizumab 💬 Omalizumab 7件: 46, 53, 65, 98, 162, 226, 299 💬
25 Asthma 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
26 Asthma 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
27 Asthma 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
28 Autoimmune thyroid disease 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
29 Autoimmune thyroid disease 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
30 Autophagy - animal 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
31 Autophagy - other 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
32 Breast cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
33 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
34 Calcium signaling pathway 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
35 Calcium signaling pathway 💬
 1件: CYSLTR1 💬 Montelukast 💬 Montelukast 8件:  6 , 13, 46, 61, 63, 85, 98, 228 💬
36 Calcium signaling pathway 💬
 1件: HRH1 💬 Loratadine 💬 Loratadine 4件: 13, 46, 89, 98 💬
37 Calcium signaling pathway 💬
 1件: HRH2 💬 Famotidine 💬 Famotidine 6件:  6 , 46, 61, 86, 98, 107 💬
38 Cellular senescence 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
39 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
40 cGMP-PKG signaling pathway 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
41 Chagas disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
42 Chemical carcinogenesis - receptor activation 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
43 Chemical carcinogenesis - receptor activation 💬
 1件: VDR 💬 Cholecalciferol 💬 Cholecalciferol 24件:  6 , 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299 💬
44 Choline metabolism in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
45 Collecting duct acid secretion 💬
 2件: ATP4A, ATP4B 💬 Dexlansoprazole 💬 Dexlansoprazole 1件: 98 💬
46 Collecting duct acid secretion 💬
 2件: ATP4A, ATP4B 💬 Esomeprazole 💬 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299 💬
47 Collecting duct acid secretion 💬
 2件: ATP4A, ATP4B 💬 Lansoprazole 💬 Lansoprazole 7件: 63, 71, 85, 98, 166, 222, 299 💬
48 Collecting duct acid secretion 💬
 2件: ATP4A, ATP4B 💬 Vonoprazan 💬 Vonoprazan 2件: 63, 98 💬
49 Colorectal cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
50 Coronavirus disease - COVID-19 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
51 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
52 Cortisol synthesis and secretion 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
53 Cushing syndrome 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
54 Cytokine-cytokine receptor interaction 💬
 1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
55 Cytokine-cytokine receptor interaction 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
56 Cytokine-cytokine receptor interaction 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
57 Cytokine-cytokine receptor interaction 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
58 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
59 Cytokine-cytokine receptor interaction 💬
 1件: TSLP 💬 Tezepelumab 💬 Tezepelumab 1件: 98 💬
60 Diabetic cardiomyopathy 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
61 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
62 Dilated cardiomyopathy 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
63 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
64 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: VDR 💬 Cholecalciferol 💬 Cholecalciferol 24件:  6 , 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299 💬
65 Endocrine resistance 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
66 Epstein-Barr virus infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
67 ErbB signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
68 Fc epsilon RI signaling pathway 💬
 1件: FCER1A 💬 Omalizumab 💬 Omalizumab 7件: 46, 53, 65, 98, 162, 226, 299 💬
69 Fc epsilon RI signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
70 Fc epsilon RI signaling pathway 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
71 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
72 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
73 FoxO signaling pathway 💬
 2件: S1PR1, S1PR4 💬 Etrasimod 💬 Etrasimod 3件: 96, 97, 98 💬
74 GABAergic synapse 💬
 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 Propofol 💬 Propofol 9件:  6 , 21, 22, 34, 46, 70, 75, 98, 296 💬
75 Gastric acid secretion 💬
 2件: ATP4A, ATP4B 💬 Dexlansoprazole 💬 Dexlansoprazole 1件: 98 💬
76 Gastric acid secretion 💬
 2件: ATP4A, ATP4B 💬 Esomeprazole 💬 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299 💬
77 Gastric acid secretion 💬
 2件: ATP4A, ATP4B 💬 Lansoprazole 💬 Lansoprazole 7件: 63, 71, 85, 98, 166, 222, 299 💬
78 Gastric acid secretion 💬
 2件: ATP4A, ATP4B 💬 Vonoprazan 💬 Vonoprazan 2件: 63, 98 💬
79 Gastric acid secretion 💬
 1件: HRH2 💬 Famotidine 💬 Famotidine 6件:  6 , 46, 61, 86, 98, 107 💬
80 Gastric cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
81 Glioma 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
82 Graft-versus-host disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
83 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
84 Hematopoietic cell lineage 💬
 1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
85 Hematopoietic cell lineage 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
86 Hematopoietic cell lineage 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
87 Hematopoietic cell lineage 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
88 Hematopoietic cell lineage 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
89 Hepatitis B 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
90 Hepatitis C 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
91 Hepatocellular carcinoma 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
92 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
93 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
94 HIF-1 signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
95 Human cytomegalovirus infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
96 Human cytomegalovirus infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
97 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
98 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
99 Human papillomavirus infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
100 Human papillomavirus infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
101 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
102 Huntington disease 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
103 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
104 IL-17 signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
105 IL-17 signaling pathway 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
106 IL-17 signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
107 Inflammatory bowel disease 💬
 1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
108 Inflammatory bowel disease 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
109 Inflammatory bowel disease 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
110 Inflammatory bowel disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
111 Inflammatory mediator regulation of TRP channels 💬
 1件: HRH1 💬 Loratadine 💬 Loratadine 4件: 13, 46, 89, 98 💬
112 Influenza A 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
113 Insulin resistance 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
114 Insulin resistance 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
115 Insulin signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
116 Intestinal immune network for IgA production 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
117 Intestinal immune network for IgA production 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
118 JAK-STAT signaling pathway 💬
 1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
119 JAK-STAT signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
120 JAK-STAT signaling pathway 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
121 JAK-STAT signaling pathway 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
122 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
123 JAK-STAT signaling pathway 💬
 1件: TSLP 💬 Tezepelumab 💬 Tezepelumab 1件: 98 💬
124 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
125 Legionellosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
126 Leishmaniasis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
127 Lipid and atherosclerosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
128 Longevity regulating pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
129 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
130 Malaria 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
131 MAPK signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
132 Metabolic pathways 💬
 2件: ATP4A, ATP4B 💬 Dexlansoprazole 💬 Dexlansoprazole 1件: 98 💬
133 Metabolic pathways 💬
 2件: ATP4A, ATP4B 💬 Esomeprazole 💬 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299 💬
134 Metabolic pathways 💬
 2件: ATP4A, ATP4B 💬 Lansoprazole 💬 Lansoprazole 7件: 63, 71, 85, 98, 166, 222, 299 💬
135 Metabolic pathways 💬
 2件: ATP4A, ATP4B 💬 Vonoprazan 💬 Vonoprazan 2件: 63, 98 💬
136 MicroRNAs in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
137 Mineral absorption 💬
 1件: VDR 💬 Cholecalciferol 💬 Cholecalciferol 24件:  6 , 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299 💬
138 Morphine addiction 💬
 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 Propofol 💬 Propofol 9件:  6 , 21, 22, 34, 46, 70, 75, 98, 296 💬
139 mTOR signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
140 mTOR signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
141 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
142 Necroptosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
143 Neuroactive ligand-receptor interaction 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
144 Neuroactive ligand-receptor interaction 💬
 1件: CYSLTR1 💬 Montelukast 💬 Montelukast 8件:  6 , 13, 46, 61, 63, 85, 98, 228 💬
145 Neuroactive ligand-receptor interaction 💬
 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 Propofol 💬 Propofol 9件:  6 , 21, 22, 34, 46, 70, 75, 98, 296 💬
146 Neuroactive ligand-receptor interaction 💬
 1件: HRH1 💬 Loratadine 💬 Loratadine 4件: 13, 46, 89, 98 💬
147 Neuroactive ligand-receptor interaction 💬
 1件: HRH2 💬 Famotidine 💬 Famotidine 6件:  6 , 46, 61, 86, 98, 107 💬
148 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Beclomethasone dipropionate 💬 Beclomethasone dipropionate 3件: 85, 97, 98 💬
149 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Budesonide 💬 Budesonide 9件: 66, 93, 94, 95, 96, 97, 98, 228, 299 💬
150 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Fluticasone 💬 Fluticasone 3件: 98, 228, 299 💬
151 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Fluticasone propionate 💬 Fluticasone propionate 2件: 98, 228 💬
152 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Mometasone 💬 Mometasone 2件: 98, 162 💬
153 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Mometasone furoate 💬 Mometasone furoate 2件: 98, 162 💬
154 Neuroactive ligand-receptor interaction 💬
 5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 Etrasimod 💬 Etrasimod 3件: 96, 97, 98 💬
155 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
156 NF-kappa B signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
157 Nicotine addiction 💬
 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 Propofol 💬 Propofol 9件:  6 , 21, 22, 34, 46, 70, 75, 98, 296 💬
158 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
159 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
160 Osteoclast differentiation 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
161 Oxidative phosphorylation 💬
 2件: ATP4A, ATP4B 💬 Dexlansoprazole 💬 Dexlansoprazole 1件: 98 💬
162 Oxidative phosphorylation 💬
 2件: ATP4A, ATP4B 💬 Esomeprazole 💬 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299 💬
163 Oxidative phosphorylation 💬
 2件: ATP4A, ATP4B 💬 Lansoprazole 💬 Lansoprazole 7件: 63, 71, 85, 98, 166, 222, 299 💬
164 Oxidative phosphorylation 💬
 2件: ATP4A, ATP4B 💬 Vonoprazan 💬 Vonoprazan 2件: 63, 98 💬
165 Pancreatic cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
166 Parathyroid hormone synthesis, secretion and action 💬
 1件: VDR 💬 Cholecalciferol 💬 Cholecalciferol 24件:  6 , 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299 💬
167 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
168 Pathways in cancer 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
169 Pathways in cancer 💬
 1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
170 Pathways in cancer 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
171 Pathways in cancer 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
172 Pathways in cancer 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
173 Pathways in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
174 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
175 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
176 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
177 Pertussis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
178 Phospholipase D signaling pathway 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
179 Phospholipase D signaling pathway 💬
 1件: FCER1A 💬 Omalizumab 💬 Omalizumab 7件: 46, 53, 65, 98, 162, 226, 299 💬
180 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
181 PI3K-Akt signaling pathway 💬
 1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
182 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
183 Prion disease 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
184 Prostate cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
185 Proteoglycans in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
186 Proteoglycans in cancer 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
187 Renin secretion 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
188 Renin-angiotensin system 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
189 Retrograde endocannabinoid signaling 💬
 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 Propofol 💬 Propofol 9件:  6 , 21, 22, 34, 46, 70, 75, 98, 296 💬
190 Rheumatoid arthritis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
191 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
192 Salmonella infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
193 Serotonergic synapse 💬
 3件: GABRB1, GABRB2, GABRB3 💬 Propofol 💬 Propofol 9件:  6 , 21, 22, 34, 46, 70, 75, 98, 296 💬
194 Serotonergic synapse 💬
 1件: SLC6A4 💬 Citalopram 💬 Citalopram 7件:  6 ,  8 , 13, 18, 46, 98, 127 💬
195 Shigellosis 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
196 Shigellosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
197 Sphingolipid signaling pathway 💬
 1件: FCER1A 💬 Omalizumab 💬 Omalizumab 7件: 46, 53, 65, 98, 162, 226, 299 💬
198 Sphingolipid signaling pathway 💬
 5件: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 Etrasimod 💬 Etrasimod 3件: 96, 97, 98 💬
199 Sphingolipid signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
200 Spinocerebellar ataxia 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
201 Synaptic vesicle cycle 💬
 1件: SLC6A4 💬 Citalopram 💬 Citalopram 7件:  6 ,  8 , 13, 18, 46, 98, 127 💬
202 Systemic lupus erythematosus 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
203 T cell receptor signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
204 T cell receptor signaling pathway 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
205 T cell receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
206 Taste transduction 💬
 6件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 💬 Propofol 💬 Propofol 9件:  6 , 21, 22, 34, 46, 70, 75, 98, 296 💬
207 TGF-beta signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
208 Th1 and Th2 cell differentiation 💬
 1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
209 Th1 and Th2 cell differentiation 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
210 Th1 and Th2 cell differentiation 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
211 Th17 cell differentiation 💬
 1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
212 Th17 cell differentiation 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
213 Thermogenesis 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
214 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
215 TNF signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
216 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
217 Toxoplasmosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
218 Tuberculosis 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
219 Tuberculosis 💬
 1件: VDR 💬 Cholecalciferol 💬 Cholecalciferol 24件:  6 , 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299 💬
220 Type I diabetes mellitus 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
221 Type II diabetes mellitus 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
222 Type II diabetes mellitus 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
223 Vascular smooth muscle contraction 💬
 1件: AGTR1 💬 Losartan 💬 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
224 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
225 Yersinia infection 💬
 1件: TNF 💬 Infliximab 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬

先頭へ